252 related articles for article (PubMed ID: 36674610)
1. Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease.
Monticelli M; Hay Mele B; Allocca M; Liguori L; Lukas J; Monti MC; Morretta E; Cubellis MV; Andreotti G
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674610
[TBL] [Abstract][Full Text] [Related]
2. Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones.
Monticelli M; Liguori L; Allocca M; Bosso A; Andreotti G; Lukas J; Monti MC; Morretta E; Cubellis MV; Hay Mele B
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563496
[TBL] [Abstract][Full Text] [Related]
3. Chaperone Therapy in Fabry Disease.
Weidemann F; Jovanovic A; Herrmann K; Vardarli I
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163813
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants.
Yam GH; Bosshard N; Zuber C; Steinmann B; Roth J
Am J Physiol Cell Physiol; 2006 Apr; 290(4):C1076-82. PubMed ID: 16531566
[TBL] [Abstract][Full Text] [Related]
5. α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.
Siekierska A; De Baets G; Reumers J; Gallardo R; Rudyak S; Broersen K; Couceiro J; Van Durme J; Schymkowitz J; Rousseau F
J Biol Chem; 2012 Aug; 287(34):28386-97. PubMed ID: 22773828
[TBL] [Abstract][Full Text] [Related]
6. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.
Benjamin ER; Flanagan JJ; Schilling A; Chang HH; Agarwal L; Katz E; Wu X; Pine C; Wustman B; Desnick RJ; Lockhart DJ; Valenzano KJ
J Inherit Metab Dis; 2009 Jun; 32(3):424-40. PubMed ID: 19387866
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease.
Lukas J; Cimmaruta C; Liguori L; Pantoom S; Iwanov K; Petters J; Hund C; Bunschkowski M; Hermann A; Cubellis MV; Rolfs A
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023956
[TBL] [Abstract][Full Text] [Related]
8. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.
Porto C; Pisani A; Rosa M; Acampora E; Avolio V; Tuzzi MR; Visciano B; Gagliardo C; Materazzi S; la Marca G; Andria G; Parenti G
J Inherit Metab Dis; 2012 May; 35(3):513-20. PubMed ID: 22187137
[TBL] [Abstract][Full Text] [Related]
9. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
Yam GH; Zuber C; Roth J
FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological chaperone therapy for Fabry disease.
Ishii S
Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(1):18-30. PubMed ID: 22241068
[TBL] [Abstract][Full Text] [Related]
11. Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests.
Andreotti G; Citro V; De Crescenzo A; Orlando P; Cammisa M; Correra A; Cubellis MV
Orphanet J Rare Dis; 2011 Oct; 6():66. PubMed ID: 22004918
[TBL] [Abstract][Full Text] [Related]
12. The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.
Besada P; Gallardo-Gómez M; Pérez-Márquez T; Patiño-Álvarez L; Pantano S; Silva-López C; Terán C; Arévalo-Gómez A; Ruz-Zafra A; Fernández-Martín J; Ortolano S
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944500
[TBL] [Abstract][Full Text] [Related]
13. Computational and modeling approaches to understand the impact of the Fabry's disease causing mutation (D92Y) on the interaction with pharmacological chaperone 1-deoxygalactonojirimycin (DGJ).
Thirumal Kumar D; Judith E; Priyadharshini Christy J; Siva R; Tayubi IA; Chakraborty C; George Priya Doss C; Zayed H
Adv Protein Chem Struct Biol; 2019; 114():341-407. PubMed ID: 30635085
[TBL] [Abstract][Full Text] [Related]
14. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy.
Lenders M; Stappers F; Niemietz C; Schmitz B; Boutin M; Ballmaier PJ; Zibert A; Schmidt H; Brand SM; Auray-Blais C; Brand E
J Med Genet; 2019 Aug; 56(8):548-556. PubMed ID: 31010832
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants.
Yu Y; Mena-Barragán T; Higaki K; Johnson JL; Drury JE; Lieberman RL; Nakasone N; Ninomiya H; Tsukimura T; Sakuraba H; Suzuki Y; Nanba E; Mellet CO; García Fernández JM; Ohno K
ACS Chem Biol; 2014 Jul; 9(7):1460-9. PubMed ID: 24783948
[TBL] [Abstract][Full Text] [Related]
16. Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study.
Andreotti G; Guarracino MR; Cammisa M; Correra A; Cubellis MV
Orphanet J Rare Dis; 2010 Dec; 5():36. PubMed ID: 21138548
[TBL] [Abstract][Full Text] [Related]
17. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
18. Flow Cytometry-Based Assay to Detect Alpha Galactosidase Enzymatic Activity at the Cellular Level.
Fekete N; Li LK; Kozma GT; Fekete G; Pállinger É; Kovács ÁF
Cells; 2024 Apr; 13(8):. PubMed ID: 38667321
[TBL] [Abstract][Full Text] [Related]
19. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease.
Khanna R; Soska R; Lun Y; Feng J; Frascella M; Young B; Brignol N; Pellegrino L; Sitaraman SA; Desnick RJ; Benjamin ER; Lockhart DJ; Valenzano KJ
Mol Ther; 2010 Jan; 18(1):23-33. PubMed ID: 19773742
[TBL] [Abstract][Full Text] [Related]
20. Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease.
Park JY; Kim GH; Kim SS; Ko JM; Lee JJ; Yoo HW
Exp Mol Med; 2009 Jan; 41(1):1-7. PubMed ID: 19287194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
